• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Rexahn Reports First Quarter 2018 Financial Results

    Gabrielle Lakusta
    May. 07, 2018 08:48AM PST
    Biotech Investing

    Rexahn Pharmaceuticals (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, announced financial results for the first quarter ended March 31, 2018. As quoted in the press release: “Rexahn had a strong start to 2018, with the presentation of encouraging data on RX-3117 in metastatic pancreatic cancer and …

    Rexahn Pharmaceuticals (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, announced financial results for the first quarter ended March 31, 2018.

    As quoted in the press release:

    “Rexahn had a strong start to 2018, with the presentation of encouraging data on RX-3117 in metastatic pancreatic cancer and advanced bladder cancer and the announced collaboration with Haichang to develop RX-0201 for hepatocellular carcinoma,” said Peter D. Suzdak, Ph.D., chief executive officer of Rexahn. “We look forward to the continued clinical advancement of RX-3117 and RX-5902 and we will be presenting data on these programs in June at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. These data will include interim data from the Phase 2a trials of RX-3117 in advanced bladder cancer patients and of RX-5902 in patients with triple-negative breast cancer. We also look forward to presenting data later this year on the ongoing Phase 2a trial of RX-3117 in combination with Abraxane® in newly diagnosed metastatic pancreatic cancer patients.”

    Click here to read the full press release.

    clinical-stage biopharmaceutical companyfinancial resultsmetastatic pancreatic cancerpancreatic cancerclinical-stage biopharmaceuticalbreast cancer
    The Conversation (0)

    Go Deeper

    AI Powered
    Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

    Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

    Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights

    Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×